,28 These findings are consistent with a model in which restored p53-mediated responses by RiBi inhibitors-MDM2i or RiBi inhibitors-etoposide combinations could play a crucial role for the induction of synthetic lethality with BH3-mimetics in BCL-2 positive DLBCL. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.